[go: up one dir, main page]

PL1725253T3 - Leki i metody leczenia bólu głowy - Google Patents

Leki i metody leczenia bólu głowy

Info

Publication number
PL1725253T3
PL1725253T3 PL05723092T PL05723092T PL1725253T3 PL 1725253 T3 PL1725253 T3 PL 1725253T3 PL 05723092 T PL05723092 T PL 05723092T PL 05723092 T PL05723092 T PL 05723092T PL 1725253 T3 PL1725253 T3 PL 1725253T3
Authority
PL
Poland
Prior art keywords
medicaments
methods
treating headache
headache
treating
Prior art date
Application number
PL05723092T
Other languages
English (en)
Inventor
Catherine C Turkel
Mitchell F Brin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PL1725253T3 publication Critical patent/PL1725253T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05723092T 2004-02-26 2005-02-15 Leki i metody leczenia bólu głowy PL1725253T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache
PCT/US2005/004778 WO2005082339A2 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache
EP05723092.2A EP1725253B1 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache

Publications (1)

Publication Number Publication Date
PL1725253T3 true PL1725253T3 (pl) 2014-08-29

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05723092T PL1725253T3 (pl) 2004-02-26 2005-02-15 Leki i metody leczenia bólu głowy

Country Status (16)

Country Link
US (10) US20050191321A1 (pl)
EP (3) EP2433643B1 (pl)
JP (1) JP4913721B2 (pl)
KR (1) KR20060126793A (pl)
CN (1) CN103251937B (pl)
AU (2) AU2005216887A1 (pl)
BR (1) BRPI0508231A (pl)
CA (2) CA2982313A1 (pl)
CY (1) CY1115104T1 (pl)
DK (1) DK1725253T3 (pl)
ES (1) ES2460731T3 (pl)
MX (1) MX337511B (pl)
PL (1) PL1725253T3 (pl)
PT (1) PT1725253E (pl)
SI (1) SI1725253T1 (pl)
WO (1) WO2005082339A2 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7223234B2 (en) * 2004-07-10 2007-05-29 Monitrix, Inc. Apparatus for determining association variables
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US20130236446A1 (en) 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
US20150231068A1 (en) 2012-03-12 2015-08-20 Miotox, Llc Treatment of Migraine Headaches with Presynaptic Neurotoxin
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2919807B1 (en) * 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
CA2907800A1 (en) 2013-03-22 2014-09-25 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
WO2015073441A1 (en) 2013-11-12 2015-05-21 Finzi Eric Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
WO2018175696A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
CA3068292A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
KR20220155351A (ko) * 2020-03-18 2022-11-22 레반스 테라퓨틱스, 아이엔씨. 두통 치료를 위한 주사용 보툴리눔 독소 방법
JP2023528453A (ja) 2020-06-03 2023-07-04 ミオトックス，エルエルシー 片頭痛障害を治療するためのゾーンおよび標的化方法および使用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69435249D1 (de) * 1993-12-28 2009-12-17 Allergan Inc Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
CA2190011C (en) 1994-05-09 2000-09-26 William J. Binder Method for reduction of headache pain
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
JP2002528421A (ja) * 1998-10-27 2002-09-03 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 創傷治癒の促進方法
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
ES2368061T3 (es) * 2000-02-08 2011-11-14 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
KR100602308B1 (ko) 2001-07-27 2006-07-18 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 여드름의 치료 또는 예방을 위한 보툴리눔 독소
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
JP2005524663A (ja) * 2002-03-01 2005-08-18 エラン ファーマシューティカルズ，インコーポレイテッド 神経エントラップメント症候群の処置方法
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1599221B1 (en) * 2003-03-06 2011-12-28 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
ATE458491T1 (de) * 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
EP2521453B1 (en) * 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) * 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
JP6377052B2 (ja) * 2012-04-03 2018-08-22 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 植物レシチンを含む毛髪化粧料組成物
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014123618A1 (en) * 2013-02-06 2014-08-14 Agilent Technologies, Inc. Fluidic coupling devices, assemblies, and related methods
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
JP6738739B2 (ja) * 2014-04-30 2020-08-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 膀胱内滴下注入用生物製剤
AU2015315571A1 (en) * 2014-09-12 2017-04-27 Allergan, Inc. Methods for treating osteoarthritis pain

Also Published As

Publication number Publication date
AU2011201107B2 (en) 2012-12-20
US8889151B2 (en) 2014-11-18
WO2005082339A2 (en) 2005-09-09
EP2752197B1 (en) 2019-11-20
CN103251937B (zh) 2015-10-07
US20090263426A1 (en) 2009-10-22
US20100189655A1 (en) 2010-07-29
EP2433643A1 (en) 2012-03-28
US7704511B2 (en) 2010-04-27
US20170128552A1 (en) 2017-05-11
CA2982313A1 (en) 2005-09-09
US20060121057A1 (en) 2006-06-08
JP4913721B2 (ja) 2012-04-11
DK1725253T3 (da) 2014-07-07
SI1725253T1 (sl) 2014-05-30
CA2557588A1 (en) 2005-09-09
CY1115104T1 (el) 2016-12-14
EP1725253A2 (en) 2006-11-29
US20220088157A1 (en) 2022-03-24
KR20060126793A (ko) 2006-12-08
JP2007525505A (ja) 2007-09-06
WO2005082339A3 (en) 2005-12-01
AU2011201107A1 (en) 2011-04-07
US20050191321A1 (en) 2005-09-01
EP2752197A1 (en) 2014-07-09
US10603366B2 (en) 2020-03-31
US9078893B2 (en) 2015-07-14
HK1098072A1 (en) 2007-07-13
US20200230217A1 (en) 2020-07-23
US20060104995A1 (en) 2006-05-18
US20190038726A1 (en) 2019-02-07
MX337511B (es) 2016-03-09
US20150313974A1 (en) 2015-11-05
CA2557588C (en) 2017-11-28
EP1725253B1 (en) 2014-04-09
HK1199403A1 (en) 2015-07-03
ES2460731T3 (es) 2014-05-14
BRPI0508231A (pt) 2007-07-17
AU2005216887A1 (en) 2005-09-09
US10092631B2 (en) 2018-10-09
EP2433643B1 (en) 2015-12-02
US9555085B2 (en) 2017-01-31
PT1725253E (pt) 2014-05-06
CN103251937A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
PL1725253T3 (pl) Leki i metody leczenia bólu głowy
EP1742570A4 (en) METHOD AND APPARATUS FOR TREATING THE BODY
EP1755733A4 (en) METHOD AND DEVICES FOR THERMAL TREATMENT
GB2425481B (en) Phototherapeutic method and apparatus
GB0822148D0 (en) Methods and apparatus
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
GB0406336D0 (en) Apparatus and method
GB0411166D0 (en) Treatment for asthma and arthritis
IL186599A0 (en) Methods for treating and preventing fibrosis
GB2411997B (en) Methods and apparatus for product authentication
EP1907596A4 (en) PLASMA TREATMENT DEVICE AND METHOD OF INJECTION TYPE
EP1852160A4 (en) METHOD AND APPARATUS PREVENTING CHILDREN
GB2415579B (en) Cryptographic method and apparatus
ZA200709443B (en) Methods for the treatment of substance abuse and dependence
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
GB0403238D0 (en) Apparatus and method
IL186262A0 (en) Authentication method and authentication unit
AP2007003949A0 (en) Apparatus and method
GB0402428D0 (en) Apparatus and method
GB0407382D0 (en) Therapeutic methods and means
EP1804703A4 (en) CRYO-SURGICAL APPARATUS AND RELATED METHODS
GB2413465B (en) Cryptographic method and apparatus
EP1809276A4 (en) PROCESSING PROCESS
GB0505964D0 (en) Products and methods for treating vaginal infections
GB0409751D0 (en) Packaging methods and apparatus